nn so se è buona...ma la posto...
Cell Therapeutics, Inc. Announces ASCO Activities
Thursday May 25, 7:00 am ET
SEATTLE, May 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC - News) today announced presentations of data on its development candidates, XYOTAX(TM) (paclitaxel poliglumex), pixantrone, and CT-2106 at the American Society of Clinical Oncology's 2005 Annual Meeting, held June 2-6 in Atlanta, Georgia.
For a complete list of the CTI activities at ASCO, please see the table
below.
Date Time Abstract Title
#
Sat., June 3 8:00 AM 7578 Comparative trial of BBR 2778
poster (pixantrone) + rituximab vs. single
agent rituximab in the treatment of
relapsed/refractory indolent
non-Hodgkin's lymphoma (NHL)
Sat., June 3 8:00 AM 7039 Effect of gender on outcome in two
poster randomized phase III trials of
Noon paclitaxel poliglumex (PPX) in
discussion chemo-naive patients with advanced
NSCLC and poor performance status
(PS2)
Sat., June 3 8:00 AM 7040 Analysis of prognostic factors in
poster patients with advanced
Noon relapsed/refractory NSCLC: Cox
discussion regression analysis of a randomized
phase III trial comparing docetaxel
and paclitaxel poliglumex (PPX)
Sun., June 4 8:00 AM 7113 Analysis of prognostic factors in
poster chemo-naive patients with advanced
NSCLC and poor performance status
(PS): Cox regression analysis of two
phase III trials
Sun., June 4 2:00 PM 2015 Phase I trial of CT-2106
poster (polyglutamated camptothecin)
5:00 PM administered weekly in patients with
discussion advanced solid tumors
For more information about the ASCO annual meeting, please refer to the conference website at
http://www.asco.org/.
In addition, CTI is a co-sponsor of the annual meeting of Women Against Lung Cancer. The plenary session includes presentation from John E. Niederhuber, M.D., Deputy Director, NCI, on NCI's plans for lung cancer and a panel discussion on estrogen and lung cancer including Jill M. Siegfried, Ph.D., from the University of Pittsburg Cancer Institute and Margaret Spitz, M.D., MPH, from The University of Texas M. D. Anderson Cancer Center. For more information, please refer to their website at
http://www.womenagainstlungcancer.org/.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit
www.cticseattle.com.
--------------------------------------------------------------------------------
Source: Cell Therapeutics, Inc.
)
Pat !
